Dela Cruz, Filemon Diolaiti, Daniel Turk, Andrew Rainey, Allison Ambesi-Impiombato, Alberto Andrews, Stuart Mansukhani, Mahesh Nagy, Peter Alvarez, Mariano Califano, Andrea Forouhar, Farhad Modzelewski, Beata Mitchell, Chelsey Yamashiro, Darrell Marks, Lianna Glade Bender, Julia Kung, Andrew Additional file 1: Figure S1. of A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma Activation of mTOR pathway in patient tumor sample. Figure S2 A. Levels of in vitro translated MAX, MAXR60Q, C-MYC, and MXD1 in samples used for EMSA. B Modeling BRAF kinase domain complexed with ATP and Mg2+. Figure S3. Validation of PDX tumor model by Sanger sequencing. Figure S4. Tumor response to selumetinib. (PDF 7254 kb) Poorly differentiated carcinoma (PDC);Patient-derived xenograft (PDX) models;Precision medicine;MAX;mTOR;BRAF;Temsirolimus;Whole exome sequencing (WES) 2016-10-31
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Figure_S1_of_A_case_study_of_an_integrative_genomic_and_experimental_therapeutic_approach_for_rare_tumors_identification_of_vulnerabilities_in_a_pediatric_poorly_differentiated_carcinoma/4347122
10.6084/m9.figshare.c.3605969_D1.v1